Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
1 other identifier
observational
160
1 country
39
Brief Summary
The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar. Also secondary objectives are: 1) to determine the clinical characteristics and outcome of the disease; and 2) to determine serotypes and antibiotic resistance patterns.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2004
Typical duration for all trials
39 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
September 27, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2006
CompletedJune 28, 2010
June 1, 2010
2.9 years
September 12, 2005
June 24, 2010
Conditions
Eligibility Criteria
Children from 0 up to 14 years of age with a diagnosis of confirmed or probable pneumococcal meningitis or with a diagnosis of suspected bacterial meningitis without bacterial or viral isolation.
You may qualify if:
- All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (39)
Unknown Facility
A Coruña, Spain
Unknown Facility
Alcalá de Henares, Spain
Unknown Facility
Alcorcón, Spain
Unknown Facility
Arrasate / Mondragón, Spain
Unknown Facility
Badalona, Spain
Unknown Facility
Barakaldo, Spain
Unknown Facility
Barcelona, Spain
Unknown Facility
Barco de Valdeorras, Spain
Unknown Facility
Bilbao, Spain
Unknown Facility
Boadilla del Monte, Spain
Unknown Facility
Cee, Spain
Unknown Facility
El Escorial, Spain
Unknown Facility
Esplugues de Llobregat, Spain
Unknown Facility
Estella-Lizarra, Spain
Unknown Facility
Ferrol, Spain
Unknown Facility
Figueres, Spain
Unknown Facility
Getafe, Spain
Unknown Facility
Girona, Spain
Unknown Facility
Granollers, Spain
Unknown Facility
Leganés, Spain
Unknown Facility
Lleida, Spain
Unknown Facility
Lugo, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Monforte de Lemos, Spain
Unknown Facility
Móstoles, Spain
Unknown Facility
Ourense, Spain
Unknown Facility
Pamplona, Spain
Unknown Facility
Pontevedra, Spain
Unknown Facility
Reus, Spain
Unknown Facility
Ribeira, Spain
Unknown Facility
Sabadell, Spain
Unknown Facility
San Sebastián, Spain
Unknown Facility
Tarragona, Spain
Unknown Facility
Terrassa, Spain
Unknown Facility
Tudela, Spain
Unknown Facility
Verín, Spain
Unknown Facility
Vigo, Spain
Unknown Facility
Vitoria-Gasteiz, Spain
Unknown Facility
Zumarraga, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Wyeth is now a wholly owned subsidiary of Pfizer
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 12, 2005
First Posted
September 27, 2005
Study Start
January 1, 2004
Primary Completion
December 1, 2006
Study Completion
December 1, 2006
Last Updated
June 28, 2010
Record last verified: 2010-06